Evidence map›Paper›PMID 34642295›Full record

ArticleCell death & disease2021

The polarity protein Par3 coordinates positively self-renewal and negatively invasiveness in glioblastoma.

Mahsa Shahidi Dadras, Laia Caja, Artur Mezheyeuski, Sijia Liu, Caroline Gélabert, Maria Catalina Gomez-Puerto, Radiosa Gallini, Carl-Johan Rubin, Peter Ten Dijke, Carl-Henrik Heldin and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 3 countries.

Mahsa Shahidi Dadras *Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Box 582, Biomedical Center, Uppsala University, SE-75123, Uppsala, Sweden.
Laia Caja *Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Box 582, Biomedical Center, Uppsala University, SE-75123, Uppsala, Sweden.ORCID 0000-0002-8786-8763
Artur MezheyeuskiDepartment of Immunology, Genetics and Pathology, Rudbeck Laboratory, Science for Life Laboratory, Uppsala University, SE-75185, Uppsala, Sweden.
Sijia LiuDepartment of Cell and Chemical Biology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands.
Caroline GélabertDepartment of Medical Biochemistry and Microbiology, Science for Life Laboratory, Box 582, Biomedical Center, Uppsala University, SE-75123, Uppsala, Sweden.
Maria Catalina Gomez-PuertoDepartment of Cell and Chemical Biology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands.
Radiosa GalliniDepartment of Immunology, Genetics and Pathology, Rudbeck Laboratory, Science for Life Laboratory, Uppsala University, SE-75185, Uppsala, Sweden.
Carl-Johan RubinDepartment of Medical Biochemistry and Microbiology, Science for Life Laboratory, Box 582, Biomedical Center, Uppsala University, SE-75123, Uppsala, Sweden.
Peter Ten DijkeDepartment of Cell and Chemical Biology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands.
Carl-Henrik HeldinDepartment of Medical Biochemistry and Microbiology, Science for Life Laboratory, Box 582, Biomedical Center, Uppsala University, SE-75123, Uppsala, Sweden.ORCID 0000-0002-9508-896X
Aristidis MoustakasDepartment of Medical Biochemistry and Microbiology, Science for Life Laboratory, Box 582, Biomedical Center, Uppsala University, SE-75123, Uppsala, Sweden. aris.moustakas@imbim.uu.se.ORCID 0000-0001-9131-3827
Uppsala University · SELeiden University Medical Center · NL

Funding

Cancerfonden (Swedish Cancer Society) CAN 2012/1186Cancerfonden (Swedish Cancer Society) CAN 2015/438Cancerfonden (Swedish Cancer Society) CAN 2016/445Cancerfonden (Swedish Cancer Society) CAN2018/469EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) 787472Ludwig Institute for Cancer Research (Ludwig Cancer Research) Uppsala BranchMagnus Bergvalls Stiftelse (Magnus Bergvall Foundation) 2019-03444Vetenskapsrådet (Swedish Research Council) 2015-02757Vetenskapsrådet (Swedish Research Council) K2013-66X-14936-10-5
6 · The paper itself

Abstract

Glioblastoma (GBM) is a brain malignancy characterized by invasiveness to the surrounding brain tissue and by stem-like cells, which propagate the tumor and may also regulate invasiveness. During brain development, polarity proteins, such as Par3, regulate asymmetric cell division of neuro-glial progenitors and neurite motility. We, therefore, studied the role of the Par3 protein (encoded by PARD3) in GBM. GBM patient transcriptomic data and patient-derived culture analysis indicated diverse levels of expression of PARD3 across and independent from subtypes. Multiplex immunolocalization in GBM tumors identified Par3 protein enrichment in SOX2-, CD133-, and NESTIN-positive (stem-like) cells. Analysis of GBM cultures of the three subtypes (proneural, classical, mesenchymal), revealed decreased gliomasphere forming capacity and enhanced invasiveness upon silencing Par3. GBM cultures with suppressed Par3 showed low expression of stemness (SOX2 and NESTIN) but higher expression of differentiation (GFAP) genes. Moreover, Par3 silencing reduced the expression of a set of genes encoding mitochondrial enzymes that generate ATP. Accordingly, silencing Par3 reduced ATP production and concomitantly increased reactive oxygen species. The latter was required for the enhanced migration observed upon silencing of Par3 as anti-oxidants blocked the enhanced migration. These findings support the notion that Par3 exerts homeostatic redox control, which could limit the tumor cell-derived pool of oxygen radicals, and thereby the tumorigenicity of GBM.

Indexed as

Cell PolarityCell Self RenewalAdaptor Proteins, Signal TransducingAdenosine TriphosphateAnimalsAntioxidantsCell Cycle ProteinsCell Line, TumorCell MovementGene Expression ProfilingGene Expression Regulation, NeoplasticGene SilencingGlioblastomaHumansMitochondriaNeoplasm InvasivenessAdaptor Proteins, Signal TransducingAdenosine TriphosphateAntioxidantsCell Cycle ProteinsPARD3 protein, humanReactive Oxygen Species

Identifiers

PMID34642295
PMCPMC8511086
OpenAlexW3205990966

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.